Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat

Vincent G. DeMarco, Javad Habibi, Adam T. Whaley-Connell, Rebecca I. Schneider, James R. Sowers, Bradley T. Andresen, Alex A. Gutweiler, Lixin Ma, Megan S. Johnson, Carlos M. Ferrario, Kevin C Dellsperger

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We have recently reported that transgenic (mRen2)27 rats (Ren2 rats) exhibit pulmonary arterial hypertension (PAH), which is, in part, mediated by oxidative stress. Since 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exhibit beneficial vascular effects independent of cholesterol synthesis, we hypothesized that rosuvastatin (RSV) treatment ameliorates PAH and pulmonary vascular remodeling in Ren2 rats, in part, by reducing oxidative stress. Six-week-old male Ren2 and Sprague-Dawley rats received RSV (10 mg·kg-1·day-1 ip) or vehicle for 3 wk. After treatment, right ventricular systolic pressure (RVSP) and mean arterial pressure (MAP) were measured. To evaluate treatment effects on pulmonary arteriole remodeling, morphometric analyses were performed to quantitate medial thickening and cell proliferation, whereas whole lung samples were used to quantitate the levels of 3-nitrotyrosine, superoxide, stable nitric oxide (NO) metabolites [nitrates and nitrites (NOx)], and expression of NO synthase isoforms. In the Ren2 rat, RVSP is normal at 5 wk of age, PAH develops between 5 and 7 wk of age, and the elevated pressure is maintained with little variation through 13 wk. At 8 wk of age, left ventricular function and blood gases were normal in the Ren2 rat. Ren2 rats exhibited elevations in medial hypertrophy due to smooth muscle cell proliferation, 3-nitrotyrosine, NO x, NADPH oxidase activity, and endothelial NO synthase expression compared with Sprague-Dawley rats. RSV significantly blunted the increase in RVSP but did not reduce MAP in the Ren2 rat; additionally, RSV significantly attenuated the elevated parameters examined in the Ren2 rat. These data suggest that statins may be a clinically viable adjunct treatment of PAH through reducing peroxynitrite formation.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume297
Issue number3
DOIs
StatePublished - Sep 1 2009

Fingerprint

Pulmonary Hypertension
Ventricular Pressure
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Blood Pressure
Lung
Sprague Dawley Rats
Arterial Pressure
Nitric Oxide
Oxidative Stress
Cell Proliferation
Hydroxymethylglutaryl CoA Reductases
Peroxynitrous Acid
Nitric Oxide Synthase Type III
NADPH Oxidase
Arterioles
Nitrites
Rosuvastatin Calcium
Left Ventricular Function
Nitric Oxide Synthase
Superoxides

Keywords

  • NADPH oxidase
  • Oxidative stress

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

DeMarco, V. G., Habibi, J., Whaley-Connell, A. T., Schneider, R. I., Sowers, J. R., Andresen, B. T., ... Dellsperger, K. C. (2009). Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. American Journal of Physiology - Heart and Circulatory Physiology, 297(3). https://doi.org/10.1152/ajpheart.00048.2009

Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. / DeMarco, Vincent G.; Habibi, Javad; Whaley-Connell, Adam T.; Schneider, Rebecca I.; Sowers, James R.; Andresen, Bradley T.; Gutweiler, Alex A.; Ma, Lixin; Johnson, Megan S.; Ferrario, Carlos M.; Dellsperger, Kevin C.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 297, No. 3, 01.09.2009.

Research output: Contribution to journalArticle

DeMarco, VG, Habibi, J, Whaley-Connell, AT, Schneider, RI, Sowers, JR, Andresen, BT, Gutweiler, AA, Ma, L, Johnson, MS, Ferrario, CM & Dellsperger, KC 2009, 'Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat', American Journal of Physiology - Heart and Circulatory Physiology, vol. 297, no. 3. https://doi.org/10.1152/ajpheart.00048.2009
DeMarco, Vincent G. ; Habibi, Javad ; Whaley-Connell, Adam T. ; Schneider, Rebecca I. ; Sowers, James R. ; Andresen, Bradley T. ; Gutweiler, Alex A. ; Ma, Lixin ; Johnson, Megan S. ; Ferrario, Carlos M. ; Dellsperger, Kevin C. / Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. In: American Journal of Physiology - Heart and Circulatory Physiology. 2009 ; Vol. 297, No. 3.
@article{4ac8e87360d54bccb9fd18483f16078d,
title = "Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat",
abstract = "We have recently reported that transgenic (mRen2)27 rats (Ren2 rats) exhibit pulmonary arterial hypertension (PAH), which is, in part, mediated by oxidative stress. Since 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exhibit beneficial vascular effects independent of cholesterol synthesis, we hypothesized that rosuvastatin (RSV) treatment ameliorates PAH and pulmonary vascular remodeling in Ren2 rats, in part, by reducing oxidative stress. Six-week-old male Ren2 and Sprague-Dawley rats received RSV (10 mg·kg-1·day-1 ip) or vehicle for 3 wk. After treatment, right ventricular systolic pressure (RVSP) and mean arterial pressure (MAP) were measured. To evaluate treatment effects on pulmonary arteriole remodeling, morphometric analyses were performed to quantitate medial thickening and cell proliferation, whereas whole lung samples were used to quantitate the levels of 3-nitrotyrosine, superoxide, stable nitric oxide (NO) metabolites [nitrates and nitrites (NOx)], and expression of NO synthase isoforms. In the Ren2 rat, RVSP is normal at 5 wk of age, PAH develops between 5 and 7 wk of age, and the elevated pressure is maintained with little variation through 13 wk. At 8 wk of age, left ventricular function and blood gases were normal in the Ren2 rat. Ren2 rats exhibited elevations in medial hypertrophy due to smooth muscle cell proliferation, 3-nitrotyrosine, NO x, NADPH oxidase activity, and endothelial NO synthase expression compared with Sprague-Dawley rats. RSV significantly blunted the increase in RVSP but did not reduce MAP in the Ren2 rat; additionally, RSV significantly attenuated the elevated parameters examined in the Ren2 rat. These data suggest that statins may be a clinically viable adjunct treatment of PAH through reducing peroxynitrite formation.",
keywords = "NADPH oxidase, Oxidative stress",
author = "DeMarco, {Vincent G.} and Javad Habibi and Whaley-Connell, {Adam T.} and Schneider, {Rebecca I.} and Sowers, {James R.} and Andresen, {Bradley T.} and Gutweiler, {Alex A.} and Lixin Ma and Johnson, {Megan S.} and Ferrario, {Carlos M.} and Dellsperger, {Kevin C}",
year = "2009",
month = "9",
day = "1",
doi = "10.1152/ajpheart.00048.2009",
language = "English (US)",
volume = "297",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat

AU - DeMarco, Vincent G.

AU - Habibi, Javad

AU - Whaley-Connell, Adam T.

AU - Schneider, Rebecca I.

AU - Sowers, James R.

AU - Andresen, Bradley T.

AU - Gutweiler, Alex A.

AU - Ma, Lixin

AU - Johnson, Megan S.

AU - Ferrario, Carlos M.

AU - Dellsperger, Kevin C

PY - 2009/9/1

Y1 - 2009/9/1

N2 - We have recently reported that transgenic (mRen2)27 rats (Ren2 rats) exhibit pulmonary arterial hypertension (PAH), which is, in part, mediated by oxidative stress. Since 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exhibit beneficial vascular effects independent of cholesterol synthesis, we hypothesized that rosuvastatin (RSV) treatment ameliorates PAH and pulmonary vascular remodeling in Ren2 rats, in part, by reducing oxidative stress. Six-week-old male Ren2 and Sprague-Dawley rats received RSV (10 mg·kg-1·day-1 ip) or vehicle for 3 wk. After treatment, right ventricular systolic pressure (RVSP) and mean arterial pressure (MAP) were measured. To evaluate treatment effects on pulmonary arteriole remodeling, morphometric analyses were performed to quantitate medial thickening and cell proliferation, whereas whole lung samples were used to quantitate the levels of 3-nitrotyrosine, superoxide, stable nitric oxide (NO) metabolites [nitrates and nitrites (NOx)], and expression of NO synthase isoforms. In the Ren2 rat, RVSP is normal at 5 wk of age, PAH develops between 5 and 7 wk of age, and the elevated pressure is maintained with little variation through 13 wk. At 8 wk of age, left ventricular function and blood gases were normal in the Ren2 rat. Ren2 rats exhibited elevations in medial hypertrophy due to smooth muscle cell proliferation, 3-nitrotyrosine, NO x, NADPH oxidase activity, and endothelial NO synthase expression compared with Sprague-Dawley rats. RSV significantly blunted the increase in RVSP but did not reduce MAP in the Ren2 rat; additionally, RSV significantly attenuated the elevated parameters examined in the Ren2 rat. These data suggest that statins may be a clinically viable adjunct treatment of PAH through reducing peroxynitrite formation.

AB - We have recently reported that transgenic (mRen2)27 rats (Ren2 rats) exhibit pulmonary arterial hypertension (PAH), which is, in part, mediated by oxidative stress. Since 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exhibit beneficial vascular effects independent of cholesterol synthesis, we hypothesized that rosuvastatin (RSV) treatment ameliorates PAH and pulmonary vascular remodeling in Ren2 rats, in part, by reducing oxidative stress. Six-week-old male Ren2 and Sprague-Dawley rats received RSV (10 mg·kg-1·day-1 ip) or vehicle for 3 wk. After treatment, right ventricular systolic pressure (RVSP) and mean arterial pressure (MAP) were measured. To evaluate treatment effects on pulmonary arteriole remodeling, morphometric analyses were performed to quantitate medial thickening and cell proliferation, whereas whole lung samples were used to quantitate the levels of 3-nitrotyrosine, superoxide, stable nitric oxide (NO) metabolites [nitrates and nitrites (NOx)], and expression of NO synthase isoforms. In the Ren2 rat, RVSP is normal at 5 wk of age, PAH develops between 5 and 7 wk of age, and the elevated pressure is maintained with little variation through 13 wk. At 8 wk of age, left ventricular function and blood gases were normal in the Ren2 rat. Ren2 rats exhibited elevations in medial hypertrophy due to smooth muscle cell proliferation, 3-nitrotyrosine, NO x, NADPH oxidase activity, and endothelial NO synthase expression compared with Sprague-Dawley rats. RSV significantly blunted the increase in RVSP but did not reduce MAP in the Ren2 rat; additionally, RSV significantly attenuated the elevated parameters examined in the Ren2 rat. These data suggest that statins may be a clinically viable adjunct treatment of PAH through reducing peroxynitrite formation.

KW - NADPH oxidase

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=69249107363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249107363&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00048.2009

DO - 10.1152/ajpheart.00048.2009

M3 - Article

VL - 297

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 3

ER -